Squalene

• USES: • For the temporary relief of the symptoms including: • circulation support • fatigue These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.

DIRECTIONS: 1-10 drops under the tongue, 3 times a day or as directed by a health professional. Consult a physician for use in children under 12 years of age.

If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, contact a physician or Poison Control Center right away. Tamper Evident: Sealed for your protection. Do not use if seal is broken or missing.

1. 1Body Temperature Increased1100%
2. 2Inflammation1100%
3. 3Oedema1100%
4. 4Staphylococcal Infection1100%

Recent PubMed references pinned to Squalene as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• [STIKO Recommendation: MF59-Adjuvanted Influenza Vaccine for Individuals ≥ 60 Years of Age].
  Deutsche medizinische Wochenschrift (1946) · 2026 · Prelog M, Gärtner B, Leischker A, et al.
  PMID 42081914DOI 10.1055/a-2812-2784
• Optimizing Bioactive Profiles in Kolovi Olive Oils: Impact of Destoning, Harvest Timing, and Postharvest Factors on Phenolic, Tocopherol, Lutein, and Squalene Content.
  Molecules (Basel, Switzerland) · 2026 · Martakos IC, Tzavellas IF, Soultani G, et al.
  PMID 41976221DOI 10.3390/molecules31071181
• Cost-effectiveness of vaccination of older adults with an MF59®-adjuvanted quadrivalent influenza vaccine compared to standard-dose and high-dose vaccines in South Korea and Taiwan.
  Vaccine · 2026 · Hsieh SM, Choi MJ, Chen YC, et al.
  PMID 41962206DOI 10.1016/j.vaccine.2026.128533
• Development and Efficacy of Enzyme-Responsive Squalene-Chidamide Nanoparticles for Pancreatic Cancer.
  Journal of visualized experiments : JoVE · 2026 · Zhou K, Zhen H, Wang W, et al.
  PMID 41911189DOI 10.3791/69875
• AS01(B)-, MF59-, and alum-based adjuvants and HIV vaccine immunogenicity: a post-hoc cross-protocol comparison of results from HVTN 100, 107, 120, and 702.
  Frontiers in immunology · 2026 · Menezes F, Chen S, Grunenberg N, et al.
  PMID 41909709DOI 10.3389/fimmu.2026.1768201
• Immunogenicity and safety of MF59-adjuvanted H5N1 pandemic influenza vaccine in healthy infants and children: a phase 2 randomized, observer-blind, multicenter study.
  Vaccine · 2026 · Põder A, Trinidad-Aseron M, Van Twuijver E, et al.
  PMID 41895156DOI 10.1016/j.vaccine.2026.128504
• Hybrid nanogel system of quercetin-loaded squalene NLCs with zinc-HA network for dry eye syndrome.
  International journal of biological macromolecules · 2026 · Mishra A, Halder J, Sahoo RK, et al.
  PMID 41802516DOI 10.1016/j.ijbiomac.2026.151215
• The Squalene Oil-in-Water Nanoemulsion Vaccine Carrier AddaVax Potentiates TLR-Induced B-Cell Responses.
  Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2026 · Pone EJ, Felgner J, Hernandez-Davies J, et al.
  PMID 41797644DOI 10.1002/cyto.a.70018

The 10 most recently updated of 25 ClinicalTrials.gov registrations naming Squalene as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• DMID 23-0015; Lassa Fever CVD 1000
  Active not recruiting · Phase 1 · Interventional · 55 enrolled · Wilbur Chen, MD, MS
  NCT06546709updated 2026-06-01
• Influenza Vaccination Strategy for Patients With Hematologic Malignancy
  Recruiting · Phase 3 · Interventional · 60 enrolled · Asan Medical Center
  NCT07485855updated 2026-03-24
• Flublok or Fluzone With Advax-CpG55.2 or AF03
  Completed · Phase 1 · Interventional · 241 enrolled · National Institute of Allergy and Infectious Diseases (NIAID)
  NCT03945825updated 2025-10-14
• Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodium Vivax."
  Not yet recruiting · Phase 1 · Interventional · 48 enrolled · Federal University of Minas Gerais
  NCT07172724updated 2025-09-15
• Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)
  Completed · Phase 2 · Interventional · 948 enrolled · Jiangsu Rec-Biotechnology Co., Ltd.
  NCT05084989updated 2024-02-29
• Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults
  Completed · Phase 1 · Interventional · 153 enrolled · Clover Biopharmaceuticals AUS Pty
  NCT05228314updated 2023-07-03
• Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)
  Completed · Phase 2 · Interventional · 300 enrolled · Jiangsu Rec-Biotechnology Co., Ltd.
  NCT05323435updated 2023-04-25
• Proof of Concept Trial of Adjuvant Activity of SWE, a Squalene-based -Oil-in-water Emulsion
  Withdrawn · Phase 1 · Interventional · 0 enrolled · Gates Medical Research Institute
  NCT05035680updated 2022-11-17
• 3Sm Challenge Model Protocol
  Completed · Interventional · 8 enrolled · Imperial College London
  NCT04753892updated 2022-07-27
• Study to Verify the Effectiveness and Safety of Isothymol or Carvacrol Compound Against SARS-CoV-2 in COVID-19 Patients
  Completed · Phase 2 · Phase 3 · Interventional · 600 enrolled · Instituto Venezolano de Investigaciones Cientificas
  NCT05445089updated 2022-07-08

Frequently asked questions

What is Squalene used for?

According to FDA labeling, Squalene carries indications including: USES: • For the temporary relief of the symptoms including: • circulation support • fatigue These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.